14q32重排激活BCL11B定义一类独特的未成熟T/髓系急性白血病
该研究在915例血液肿瘤中筛查14q32/BCL11B重排,发现20例未成熟急性白血病(占AML的4%、T-ALL的3.6%),表型覆盖AML-M0/M1、T/髓系混合表型急性白血病及ETP-ALL。重排导致BCL11B激活,伴FLT3及表观调控基因变异,转录组可将其与AML、T-ALL、ETP-ALL区分,并有体外药物敏感谱。
要点
- 14q32/BCL11B重排是这类未成熟急性白血病的细胞遗传学标志。
- BCL11B表达见于诊断时而不见于缓解期,可作疾病生物标志物。
- 常合并FLT3及DNMT3A、TET2、WT1等表观调控基因变异。
核心结论
- 14q32/BCL11B重排激活BCL11B,标记一类表型广泛的未成熟急性白血病,不同于典型AML与T-ALL。
研究设计与样本
- 研究在915例血液肿瘤中筛查14q32/BCL11B重排,包括202例AML与333例T-ALL。
- 鉴定出20例未成熟白血病,含4种14q32/BCL11B易位类型。
- 采用转录组分析与体外药物敏感性分析。
主要发现
- 20例未成熟白血病占AML的4%、T-ALL的3.6%。
- 易位类型:t(2;14)(q22.3;q32) 7例、t(6;14)(q25.3;q32) 9例、t(7;14)(q21.2;q32) 2例、t(8;14)(q24.2;q32) 2例。
- t(2;14)产生ZEB2-BCL11B融合转录本,其余3种易位将转录活跃增强子序列移至BCL11B附近而不产生融合基因。
- 所有易位均导致BCL11B激活,BCL11B表达见于诊断时而不见于缓解期。
- BCL11B失调常与FLT3及DNMT3A、TET2和/或WT1基因变异共存。
关键数值与推荐
- 915例血液肿瘤筛查中鉴定20例14q32/BCL11B重排未成熟白血病。
- 4种易位例数分别为7、9、2、2例。
临床怎么用
- 对表型覆盖AML-M0/M1、T/髓MPAL与ETP-ALL的未成熟白血病应检测14q32/BCL11B重排。
- BCL11B表达可作为诊断与缓解监测的生物标志物。
- 合并FLT3及表观调控基因变异提示需纳入分子评估。
局限性
- 为筛查性研究,未报告各易位类型的完整临床特征与预后数据。
- 体外药物敏感性结果尚未在临床治疗中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute leukemias (ALs) of ambiguous lineage are a heterogeneous group of high-risk leukemias characterized by coexpression of myeloid and lymphoid markers. In this study, we identified a distinct subgroup of immature acute leukemias characterized by a broadly variable phenotype, covering acute myeloid leukemia (AML, M0 or M1), T/myeloid mixed-phenotype acute leukemia (T/M MPAL), and early T-cell precursor acute lymphoblastic leukemia (ETP-ALL). Rearrangements at 14q32/BCL11B are the cytogenetic hallmark of this entity. In our screening of 915 hematological malignancies, there were 202 AML and 333 T-cell acute lymphoblastic leukemias (T-ALL: 58, ETP; 178, non-ETP; 8, T/M MPAL; 89, not otherwise specified). We identified 20 cases of immature leukemias (4% of AML and 3.6% of T-ALL), harboring 4 types of 14q32/BCL11B translocations: t(2,14)(q22.3;q32) (n = 7), t(6;14)(q25.3;q32) (n = 9), t(7;14)(q21.2;q32) (n = 2), and t(8;14)(q24.2;q32) (n = 2). The t(2;14) produced a ZEB2-BCL11B fusion transcript, whereas the other 3 rearrangements displaced transcriptionally active enhancer sequences close to BCL11B without producing fusion genes. All translocations resulted in the activation of BCL11B, a regulator of T-cell differentiation associated with transcriptional corepressor complexes in mammalian cells. The expression of BCL11B behaved as a disease biomarker that was present at diagnosis, but not in remission. Deregulation of BCL11B co-occurred with variants at FLT3 and at epigenetic modulators, most frequently the DNMT3A, TET2, and/or WT1 genes. Transcriptome analysis identified a specific expression signature, with significant downregulation of BCL11B targets, and clearly separating BCL11B AL from AML, T-ALL, and ETP-ALL. Remarkably, an ex vivo drug-sensitivity profile identified a panel of compounds with effective antileukemic activity.
引用
- Di Giacomo D, La Starza R, Gorello P, et al. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia. Blood. 2021. PMID: 33876209. doi:10.1182/blood.2020010510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。